^
Association details:
| Biomarker: | IDH1 mutation + MYC amplification + MAPRE1 overexpression |
|---|---|
| Cancer: | Glioblastoma |
| Drug: | lisavanbulin (BAL101553) (Apoptosis stimulant, Vascular disrupting agent, Microtubule destabilizing agent) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
382P - The potential utility of end-binding protein 1 (EB1) as response-predictive biomarker for lisavanbulin: Final results from a phase I study of lisavanbulin (BAL101553) in adult patients with recurrent glioblastoma (GBM)
Published date:
09/14/2020
Excerpt:
One patient with an IDH-mutated, C-MYC amplified GBM with high EB1 expression had a partial response at 25 mg/d (88% area reduction per RANO) and continues on study >24 months.
Trial ID:
